At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 421 enrolled
Drug / intervention
EDP1815 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Multicenter, Double-Blind, Placebo-Controlled, Multiple-Cohort Study Investigating the Effect of EDP1815 in Participants for the Treatment of Mild, Moderate and Severe Atopic Dermatitis
In Brief
A Phase 2 clinical trial evaluating EDP1815 and Placebo for Atopic Dermatitis. Completed, enrolled 421 participants across 59 sites in 6 countries.
Detailed Summary
The purpose of this research study is to determine whether the study drug, EDP1815, is safe and effective in the treatment of atopic dermatitis compared with placebo. The study will look at different doses of the study drug, and whether there are differences when the drug is given once daily or twice daily.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAtopic Dermatitis
CountriesAustralia, Bulgaria, Canada, Germany, Poland, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20222023202420252026
First PostedNov 2021
Enrollment StartJan 2022
Primary CompletionMar 2023
Study CompletionMar 2023
TodayJul 2026
First PostedNov 16, 2021
Enrollment StartJan 31, 2022
Primary CompletionMar 9, 2023
Study CompletionMar 28, 2023
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 4.6 years ago
Interventions
EDP1815drug
EDP1815 is an orally administered, pharmaceutical preparation of a single strain of bacteria
Placebodrug
Placebo oral capsule